Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 10
Submit an article Journal homepage
731
Views
6
CrossRef citations to date
0
Altmetric
Oncology

Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data

Chakkarin BurudpakdeeIMS Health, Fairfax, VA, USA; ;University of North Carolina at Charlotte, Charlotte, NC, USA; Correspondence[email protected]
,
Huamao Mark LinMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;
,
Weiying WangNucleusX Market Access, Warren, NJ, USA;
,
Arpamas SeetasithIMS Health, Fairfax, VA, USA;
,
Yanyan ZhuMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;
,
Vijayveer BonthapallyMillennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;
&
Kenneth R. CarsonWashington University School of Medicine, St. Louis, MO, USA
 show all
Pages 965-972 | Received 04 Sep 2015, Accepted 28 Apr 2016, Published online: 26 May 2016

References

  • Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol 2014;51:25-34
  • Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30
  • Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756-67
  • Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. http://seer.cancer.gov/csr/1975_2011 (based on November 2013 SEER data submission, posted to the SEER website Apri 2014 Accessed March 31, 2015
  • Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103:2091-8
  • Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL–U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9
  • Lunning MA, Horwitz S. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data? Curr Treat Options Oncol 2013;14:212-23
  • Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857-77
  • National Comprehensive Cancer Network (NCCN). NCCN clinical pracrtice guidelines in oncology: Non-Hodgkin's Lymphoma. Version 2. 2015 https://www.tri-kobe.org/nccn/guideline/hematologic/nhl/english/bcel.pdf [Accessed March 31, 2015]
  • Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970-6
  • Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma 2006;47:1535-44
  • d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093-9
  • Abouyabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front–line anthracycline–based chemotherapy regimens for peripheral T-cell Lymphoma. ISRN Hematol 2011;2011:623924
  • Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood 2014;123:2636-44
  • Kruse GB, Potashman MH, Stavrakas S, et al. Administration costs of intravenous chemotherapy in treating peripheral T-cell lymphoma. J Med Econ 2014;17:446-58
  • Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004;22:3524-30
  • Setoguchi S, Solomon DH, Glynn RJ, et al. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 2007;18:561-9
  • Spectrum Pharmaceuticals Inc. BELEODAQ® (belinostat) for injection, for intravenous administration. Full prescribinginformation (July 2014). Spectrum Pharmaceuticals Inc., Handerson, NV, 2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf. Accessed March 31, 2015

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.